Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Given Average Rating of “Moderate Buy” by Brokerages

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) has received an average recommendation of “Moderate Buy” from the seven brokerages that are covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and five have assigned a buy recommendation to the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $24.4167.

Several brokerages have recently weighed in on ADPT. TD Cowen upped their target price on shares of Adaptive Biotechnologies from $25.00 to $28.00 and gave the company a “buy” rating in a research note on Thursday, July 30th. Morgan Stanley boosted their price objective on shares of Adaptive Biotechnologies from $20.00 to $22.00 and gave the stock an “equal weight” rating in a report on Thursday, July 30th. JPMorgan Chase & Co. decreased their price objective on shares of Adaptive Biotechnologies from $21.00 to $19.00 and set an “overweight” rating for the company in a research report on Wednesday, May 6th. BTIG Research lifted their target price on Adaptive Biotechnologies from $24.00 to $25.00 and gave the stock a “buy” rating in a research report on Thursday, July 30th. Finally, Piper Sandler boosted their price target on Adaptive Biotechnologies from $20.00 to $27.50 and gave the stock an “overweight” rating in a research note on Tuesday, August 4th.

Insider Activity at Adaptive Biotechnologies

In other Adaptive Biotechnologies news, Director Robert Hershberg sold 30,664 shares of the company’s stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $24.40, for a total value of $748,201.60. Following the transaction, the director directly owned 46,683 shares of the company’s stock, valued at $1,139,065.20. This represents a 39.64% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Harlan S. Robins sold 492,400 shares of the stock in a transaction that occurred on Tuesday, July 21st. The shares were sold at an average price of $21.89, for a total value of $10,778,636.00. Following the transaction, the insider owned 812,058 shares of the company’s stock, valued at approximately $17,775,949.62. This trade represents a 37.75% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 2,062,325 shares of company stock worth $46,659,069 over the last ninety days. Company insiders own 5.70% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. BlackRock Inc. bought a new stake in Adaptive Biotechnologies in the second quarter valued at about $324,735,000. Ameriprise Financial Inc. lifted its position in shares of Adaptive Biotechnologies by 84.3% in the 3rd quarter. Ameriprise Financial Inc. now owns 5,971,706 shares of the company’s stock worth $89,337,000 after buying an additional 2,731,648 shares during the last quarter. Wellington Management Group LLP boosted its holdings in shares of Adaptive Biotechnologies by 53.2% in the 2nd quarter. Wellington Management Group LLP now owns 5,911,366 shares of the company’s stock valued at $126,799,000 after buying an additional 2,053,944 shares during the period. Price T Rowe Associates Inc. MD grew its position in shares of Adaptive Biotechnologies by 303.4% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 4,387,361 shares of the company’s stock valued at $71,252,000 after buying an additional 3,299,635 shares during the last quarter. Finally, Westfield Capital Management Co. LP acquired a new stake in Adaptive Biotechnologies during the fourth quarter worth about $65,942,000. 99.17% of the stock is owned by institutional investors and hedge funds.

Adaptive Biotechnologies Stock Performance

Shares of NASDAQ:ADPT opened at $26.44 on Friday. The business’s 50-day simple moving average is $22.76 and its 200 day simple moving average is $17.59. The company has a market cap of $4.22 billion, a P/E ratio of -64.49 and a beta of 2.08. The company has a debt-to-equity ratio of 2.22, a quick ratio of 4.68 and a current ratio of 4.79. Adaptive Biotechnologies has a one year low of $12.00 and a one year high of $26.87.

Adaptive Biotechnologies (NASDAQ:ADPT) last issued its quarterly earnings data on Wednesday, July 29th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.12). The firm had revenue of $71.55 million during the quarter, compared to analyst estimates of $65.44 million. Adaptive Biotechnologies had a negative net margin of 20.73% and a negative return on equity of 36.81%. The firm’s revenue was up 21.5% compared to the same quarter last year. During the same period last year, the business earned ($0.17) EPS. On average, sell-side analysts forecast that Adaptive Biotechnologies will post -0.4 earnings per share for the current fiscal year.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.